REPLIGEN CORP (RGEN) Stock Fundamental Analysis
NASDAQ:RGEN - Nasdaq - US7599161095 - Common Stock - Currency: USD
RGEN gets a fundamental rating of 5 out of 10. The analysis compared the fundamentals against 55 industry peers in the Life Sciences Tools & Services industry. RGEN has an excellent financial health rating, but there are some minor concerns on its profitability. RGEN is valued quite expensive, but it does show an excellent growth.
1. Profitability
1.1 Basic Checks
RGEN had positive earnings in the past year.
In the past year RGEN had a positive cash flow from operations.
RGEN had positive earnings in 4 of the past 5 years.
In the past 5 years RGEN always reported a positive cash flow from operatings.
1.2 Ratios
With a decent Return On Assets value of -0.69%, RGEN is doing good in the industry, outperforming 63.64% of the companies in the same industry.
RGEN's Return On Equity of -0.99% is fine compared to the rest of the industry. RGEN outperforms 67.27% of its industry peers.
RGEN has a Return On Invested Capital (0.48%) which is in line with its industry peers.
RGEN had an Average Return On Invested Capital over the past 3 years of 2.65%. This is significantly below the industry average of 13.60%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -0.69% | ||
| ROE | -0.99% | ||
| ROIC | 0.48% |
ROA(3y)2.57%
ROA(5y)3.26%
ROE(3y)3.42%
ROE(5y)4.3%
ROIC(3y)2.65%
ROIC(5y)3.3%
1.3 Margins
RGEN has a Operating Margin (2.56%) which is comparable to the rest of the industry.
In the last couple of years the Operating Margin of RGEN has declined.
The Gross Margin of RGEN (51.03%) is comparable to the rest of the industry.
RGEN's Gross Margin has declined in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 2.56% | ||
| PM (TTM) | N/A | ||
| GM | 51.03% |
OM growth 3Y-58.46%
OM growth 5Y-32.3%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-4.88%
GM growth 5Y-2.12%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so RGEN is destroying value.
RGEN has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, RGEN has more shares outstanding
RGEN has a better debt/assets ratio than last year.
2.2 Solvency
RGEN has an Altman-Z score of 5.80. This indicates that RGEN is financially healthy and has little risk of bankruptcy at the moment.
The Altman-Z score of RGEN (5.80) is better than 89.09% of its industry peers.
The Debt to FCF ratio of RGEN is 4.42, which is a neutral value as it means it would take RGEN, 4.42 years of fcf income to pay off all of its debts.
RGEN has a Debt to FCF ratio of 4.42. This is in the better half of the industry: RGEN outperforms 69.09% of its industry peers.
RGEN has a Debt/Equity ratio of 0.27. This is a healthy value indicating a solid balance between debt and equity.
With a Debt to Equity ratio value of 0.27, RGEN perfoms like the industry average, outperforming 54.55% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.27 | ||
| Debt/FCF | 4.42 | ||
| Altman-Z | 5.8 |
ROIC/WACC0.05
WACC9.68%
2.3 Liquidity
A Current Ratio of 6.79 indicates that RGEN has no problem at all paying its short term obligations.
RGEN has a Current ratio of 6.79. This is amongst the best in the industry. RGEN outperforms 87.27% of its industry peers.
A Quick Ratio of 5.79 indicates that RGEN has no problem at all paying its short term obligations.
The Quick ratio of RGEN (5.79) is better than 85.45% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 6.79 | ||
| Quick Ratio | 5.79 |
3. Growth
3.1 Past
RGEN shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 16.06%, which is quite good.
RGEN shows a small growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 7.11% yearly.
The Revenue has grown by 32.28% in the past year. This is a very strong growth!
The Revenue has been growing by 18.62% on average over the past years. This is quite good.
EPS 1Y (TTM)16.06%
EPS 3Y-21.5%
EPS 5Y7.11%
EPS Q2Q%39.29%
Revenue 1Y (TTM)32.28%
Revenue growth 3Y-1.83%
Revenue growth 5Y18.62%
Sales Q2Q%11.8%
3.2 Future
The Earnings Per Share is expected to grow by 25.08% on average over the next years. This is a very strong growth
RGEN is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 15.37% yearly.
EPS Next Y15.7%
EPS Next 2Y21.77%
EPS Next 3Y23.52%
EPS Next 5Y25.08%
Revenue Next Year11.75%
Revenue Next 2Y13.04%
Revenue Next 3Y13.99%
Revenue Next 5Y15.37%
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
RGEN is valuated quite expensively with a Price/Earnings ratio of 79.85.
Compared to the rest of the industry, the Price/Earnings ratio of RGEN is on the same level as its industry peers.
When comparing the Price/Earnings ratio of RGEN to the average of the S&P500 Index (27.28), we can say RGEN is valued expensively.
RGEN is valuated quite expensively with a Price/Forward Earnings ratio of 57.85.
RGEN's Price/Forward Earnings ratio is in line with the industry average.
RGEN's Price/Forward Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 21.76.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 79.85 | ||
| Fwd PE | 57.85 |
4.2 Price Multiples
RGEN's Enterprise Value to EBITDA ratio is in line with the industry average.
The rest of the industry has a similar Price/Free Cash Flow ratio as RGEN.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 59.57 | ||
| EV/EBITDA | 61.07 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates RGEN does not grow enough to justify the current Price/Earnings ratio.
A more expensive valuation may be justified as RGEN's earnings are expected to grow with 23.52% in the coming years.
PEG (NY)5.09
PEG (5Y)11.24
EPS Next 2Y21.77%
EPS Next 3Y23.52%
5. Dividend
5.1 Amount
No dividends for RGEN!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
126.96
+0.52 (+0.41%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners104.63%
Inst Owner Change2.88%
Ins Owners0.51%
Ins Owner Change-0.5%
Market Cap7.13B
Analysts80
Price Target187.27 (47.5%)
Short Float %6.47%
Short Ratio4.28
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)7.97%
Min EPS beat(2)5.21%
Max EPS beat(2)10.73%
EPS beat(4)3
Avg EPS beat(4)10.26%
Min EPS beat(4)-0.8%
Max EPS beat(4)25.89%
EPS beat(8)5
Avg EPS beat(8)9.59%
EPS beat(12)9
Avg EPS beat(12)11.22%
EPS beat(16)13
Avg EPS beat(16)15.65%
Revenue beat(2)1
Avg Revenue beat(2)-0.4%
Min Revenue beat(2)-2.03%
Max Revenue beat(2)1.23%
Revenue beat(4)1
Avg Revenue beat(4)-0.93%
Min Revenue beat(4)-2.03%
Max Revenue beat(4)1.23%
Revenue beat(8)1
Avg Revenue beat(8)-1.77%
Revenue beat(12)3
Avg Revenue beat(12)-0.5%
Revenue beat(16)7
Avg Revenue beat(16)1.4%
PT rev (1m)0%
PT rev (3m)-3.02%
EPS NQ rev (1m)1.38%
EPS NQ rev (3m)-5.89%
EPS NY rev (1m)0.21%
EPS NY rev (3m)-1.55%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0.88%
Revenue NY rev (1m)0%
Revenue NY rev (3m)1.71%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 79.85 | ||
| Fwd PE | 57.85 | ||
| P/S | 8.88 | ||
| P/FCF | 59.57 | ||
| P/OCF | 48.96 | ||
| P/B | 3.59 | ||
| P/tB | 14.44 | ||
| EV/EBITDA | 61.07 |
EPS(TTM)1.59
EY1.25%
EPS(NY)2.19
Fwd EY1.73%
FCF(TTM)2.13
FCFY1.68%
OCF(TTM)2.59
OCFY2.04%
SpS14.3
BVpS35.34
TBVpS8.79
PEG (NY)5.09
PEG (5Y)11.24
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -0.69% | ||
| ROE | -0.99% | ||
| ROCE | 0.76% | ||
| ROIC | 0.48% | ||
| ROICexc | 0.65% | ||
| ROICexgc | 2.53% | ||
| OM | 2.56% | ||
| PM (TTM) | N/A | ||
| GM | 51.03% | ||
| FCFM | 14.9% |
ROA(3y)2.57%
ROA(5y)3.26%
ROE(3y)3.42%
ROE(5y)4.3%
ROIC(3y)2.65%
ROIC(5y)3.3%
ROICexc(3y)3.74%
ROICexc(5y)4.93%
ROICexgc(3y)17.96%
ROICexgc(5y)N/A
ROCE(3y)4.23%
ROCE(5y)5.26%
ROICexcg growth 3Y-71.22%
ROICexcg growth 5Y-37.94%
ROICexc growth 3Y-63.64%
ROICexc growth 5Y-32.38%
OM growth 3Y-58.46%
OM growth 5Y-32.3%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-4.88%
GM growth 5Y-2.12%
F-Score5
Asset Turnover0.28
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.27 | ||
| Debt/FCF | 4.42 | ||
| Debt/EBITDA | 4.66 | ||
| Cap/Depr | 27.92% | ||
| Cap/Sales | 3.23% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 128.29% | ||
| Profit Quality | N/A | ||
| Current Ratio | 6.79 | ||
| Quick Ratio | 5.79 | ||
| Altman-Z | 5.8 |
F-Score5
WACC9.68%
ROIC/WACC0.05
Cap/Depr(3y)88.31%
Cap/Depr(5y)109.53%
Cap/Sales(3y)7.3%
Cap/Sales(5y)7.94%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)16.06%
EPS 3Y-21.5%
EPS 5Y7.11%
EPS Q2Q%39.29%
EPS Next Y15.7%
EPS Next 2Y21.77%
EPS Next 3Y23.52%
EPS Next 5Y25.08%
Revenue 1Y (TTM)32.28%
Revenue growth 3Y-1.83%
Revenue growth 5Y18.62%
Sales Q2Q%11.8%
Revenue Next Year11.75%
Revenue Next 2Y13.04%
Revenue Next 3Y13.99%
Revenue Next 5Y15.37%
EBIT growth 1Y739.35%
EBIT growth 3Y-59.22%
EBIT growth 5Y-19.7%
EBIT Next Year68.28%
EBIT Next 3Y40.73%
EBIT Next 5Y36.8%
FCF growth 1Y32.01%
FCF growth 3Y45.03%
FCF growth 5Y27.02%
OCF growth 1Y-9.06%
OCF growth 3Y13.8%
OCF growth 5Y21.15%